Research analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reduced their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th.
View Our Latest Report on NERV
Minerva Neurosciences Price Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, sell-side analysts expect that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Stories
- Five stocks we like better than Minerva Neurosciences
- Election Stocks: How Elections Affect the Stock Market
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What Are Growth Stocks and Investing in Them
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Low PE Growth Stocks: Unlocking Investment Opportunities
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.